2007 Press releases

The investment bank ABG Sundal Collier Norge ASA will from 20 December 2007 quote bid and ask prices in the Clavis Pharma share in ...

Clavis Pharma ASA announced today the appointment of Jan Alfheim as Chief Business Officer. Mr. Alfheim has ..

Clavis Pharma today announced that the European Commission has granted orphan drug designation to ELACYT^TM for the treatment of Acute Myeloid Leukaemia ...

Mr. Geir Christian Melen has been appointed as the new Chief Executive Officer of Clavis Pharma. Mr. Melen will take up his new responsibilities as ...

Clavis Pharma ASA continued its research and development focus during the second quarter 2007, with three cancer drug candidates in development. ..

This new phase II clinical study has recently been approved by health authorities in the Norway and Sweden and is the first clinical trial where ELACYT ...

Clavis Pharma (OSE: CLAVIS) presented an update of data from its ongoing clinical Phase I/II study with ELACYT in hematologic cancers ...

Clavis Pharma announced today that the company presented the first preliminary data from its clinical Phase I/II study with ELACYT ...